Kikuchi, Jun

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Rheumatology) (Shinanomachi)

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)

 

Research Areas 【 Display / hide

  • Life Science / Connective tissue disease and allergy

Research Keywords 【 Display / hide

  • Systemic lupus erythematosus

  • Rheumatoid arthritis

 

Papers 【 Display / hide

  • 大量ステロイドとトシリズマブ治療経過中に巨細胞性動脈炎による重症脳梗塞を発症した一例

    鈴木 浩司, 秋山 光浩, 花岡 洋成, 近藤 泰, 齋藤 俊太郎, 菊池 潤, 金子 祐子

    関東リウマチ (関東リウマチ研究会)  55   7 - 11 2023.05

    ISSN  0911-4807

     View Summary

    症例は77歳女性で、発熱、両肩関節の疼痛・挙上困難、顎跛行を主訴とした。血液検査、画像所見(PET-CT、頭部造影MRI)、右側頭動脈生検より、巨細胞性動脈炎と診断した。大量ステロイドとトシリズマブを開始したが、重症脳梗塞を発症し、ステロイドパルスとシクロフォスファミドによる再寛解導入療法を行い、病勢をコントロールできた。脳梗塞に対してはアスピリンとクロピドグレルを開始した。本症例は高齢、高血圧、顎跛行、炎症マーカー低値で、PET-CTで内頸動脈への集積亢進を認めるなど脳梗塞のリスクが高かった。

  • Deep remission within 12 months prevents renal flare and damage accrual in lupus nephritis.

    Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Takeuchi T, Kaneko Y

    Clinical and experimental rheumatology  2023.01

    ISSN  0392-856X

  • Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients.

    Saito S, Suzuki K, Yoshimoto K, Kondo Y, Kikuchi J, Hanaoka H, Kaneko Y, Takeuchi T

    Clinical and experimental rheumatology  2022.12

    ISSN  0392-856X

  • Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment.

    Hiroshi Takei, Satoshi Takanashi, Kotaro Otomo, Hironari Hanaoka, Jun Kikuchi, Kunihiro Yamaoka, Keiko Yoshimoto, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko

    Modern rheumatology  2022.12

    ISSN  1439-7595

     View Summary

    OBJECTIVE: To investigate the efficacy and safety of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA). METHODS: Patients with active RA, despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), were recruited. HCQ was administered for 24 weeks, in addition to prior treatment. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 achievement at week 24, compared to that of a propensity score matched historical control group. RESULTS: Sixty patients were enrolled and administered HCQ. We also identified 276 patients as candidates for the historical control group. Propensity score matching yielded 46 patients in each group. The proportion of ACR20 achievements at week 24 was significantly higher in the HCQ group than that in the control group (54.4% vs. 28.3%, P = 0.007). The proportion of ACR50 and ACR70 achievement at week 24 were also higher in the HCQ group than those in the control group (ACR50, 30.4% vs. 4.3%, P = 0.006; ACR70, 17.4% vs. 0%, P = 0.005). Neither hydroxychloroquine retinopathy nor any new safety signal was observed during the study. CONCLUSION: The addition of HCQ to csDMARDs was effective, with no new safety signal in patients with RA.

  • Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study

    Kandane-Rathnayake R., Golder V., Louthrenoo W., Chen Y.H., Cho J., Lateef A., Hamijoyo L., Luo S.F., Wu Y.J.J., Navarra S.V., Zamora L., Li Z., Sockalingam S., Katsumata Y., Harigai M., Hao Y., Zhang Z., Basnayake B.M.D.B., Chan M., Kikuchi J., Takeuchi T., Bae S.C., Oon S., O'Neill S., Goldblatt F., Ng K.P.L., Law A., Tugnet N., Kumar S., Tee C., Tee M., Ohkubo N., Tanaka Y., Yu D.Y., Karyekar C.S., Sing Lau C., Monk J.A., Nikpour M., Hoi A., Morand E.F.

    The Lancet Rheumatology (The Lancet Rheumatology)  4 ( 12 ) e822 - e830 2022.12

     View Summary

    Background: Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have been validated to protect against organ damage and to improve quality of life. We aimed to investigate the association between lupus low disease activity state (LLDAS) and remission and risk of mortality in patients with SLE. We hypothesised that LLDAS has a protective association with mortality risk. Methods: In this prospective, multinational, longitudinal cohort study, we used data from patients with SLE in the Asia Pacific Lupus Collaboration cohort collected between May 1, 2013, and Dec 31, 2020. Eligible patients were adults (aged ≥18 years) who met either the 1997 American College of Rheumatology modified classification criteria for SLE or the 2012 Systemic Lupus International Collaborating Clinics classification criteria. The primary outcome was all-cause mortality, and LLDAS, remission, and variations of remission with lower glucocorticoid thresholds were the primary exposure variables. Survival analyses were used to examine longitudinal associations between these endpoints and risk of mortality. This study is registered with ClinicalTrials.gov, NCT03138941. Findings: Among a total of 4106 patients in the cohort, 3811 (92·8%) patients were included in the final analysis (median follow-up 2·8 years [IQR 1·0–5·3]; 3509 [92·1%] women and 302 [7·9%] men), of whom 80 died during the observation period (crude mortality rate 6·4 deaths per 1000 person-years). LLDAS was attained at least once in 43 (53·8%) of 80 participants who died and in 3035 (81·3%) of 3731 participants who were alive at the end of the study (p<0·0001); 22 (27·5%) participants who died versus 1966 (52·7%) who were alive at the end of the study attained LLDAS for at least 50% of observed time (p<0·0001). Remission was attained by 32 (40·0%) of 80 who died and in 2403 (64·4%) of 3731 participants who were alive at the end of the study (p<0·0001); 14 (17·5%) participants who died versus 1389 (37·2%) who were alive at the end of the study attained remission for at least 50% of observed time (p<0·0001). LLDAS for at least 50% of observed time (adjusted hazard ratio 0·51 [95% CI 0·31–0·85]; p=0·010) and remission for at least 50% of observed time (0·52 [0·29–0·93]; p=0·027) were associated with reduced risk of mortality. Modifying the remission glucocorticoid threshold (<5·0 mg/day prednisolone) was more protective against mortality than current remission definitions (0·31 [0·12–0·77]; p=0·012), and glucocorticoid-free remission was the most protective (0·13 [0·02–0·96]; p=0·046). Interpretation: LLDAS significantly reduced the risk of mortality in patients with SLE. Remission did not further reduce the risk of mortality compared with LLDAS, unless lower glucocorticoid thresholds were used. Funding: The Asia-Pacific Lupus Collaboration received funding from Janssen, Bristol Myers Squibb, Eli Lilly, and UCB for this study.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 皮膚エリテマトーデスの精査中に中毒性表皮壊死症様皮疹をきたし全身性エリテマトーデスの診断に至った症例

    鈴木 悠史, 鈴木 浩司, 秋山 光浩, 近藤 泰, 齋藤 俊太郎, 菊池 潤, 花岡 洋成, 金子 祐子

    日本リウマチ学会関東支部学術集会プログラム・抄録集 (日本リウマチ学会-関東支部)  33回   62 - 62 2023.12

  • 全身性エリテマトーデス患者におけるSARS-CoV-2 mRNAワクチン投与後の再燃は投与前の疾患活動性と関連する

    菊池 潤, 近藤 泰, 小島 修一郎, 葛西 志保, 堺 優真, 竹下 勝, 平本 和音, 齋藤 俊太郎, 福井 裕之, 花岡 洋成, 金子 祐子

    日本臨床免疫学会総会プログラム・抄録集 ((一社)日本臨床免疫学会)  51回   122 - 122 2023.10

  • 入院しステロイド療法を行ったリウマチ膠原病患者のサルコペニアの進行と関連する因子の探索

    花岡 洋成, 菊池 潤, 平本 和音, 秋山 光浩, 齋藤 俊太郎, 近藤 泰, 金子 祐子

    日本臨床免疫学会総会プログラム・抄録集 ((一社)日本臨床免疫学会)  51回   118 - 118 2023.10

  • 高齢発症SLE・その他 全身性エリテマトーデス患者におけるSARS-CoV-2 mRNAワクチン投与後の再燃は投与前の疾患活動性と関連する

    菊池 潤, 近藤 泰, 竹下 勝, 平本 和音, 齋藤 俊太郎, 福井 裕之, 花岡 洋成, 鈴木 勝也, 金子 祐子

    日本リウマチ学会総会・学術集会プログラム・抄録集 ((一社)日本リウマチ学会)  67回   556 - 556 2023.03

  • 関節リウマチ患者におけるSARS-CoV-2ワクチン接種後の疾患増悪に関する検討

    小島 修一郎, 近藤 泰, 堺 優真, 葛西 志保, 竹下 勝, 菊池 潤, 花岡 洋成, 鈴木 勝也, 金子 祐子

    日本リウマチ学会総会・学術集会プログラム・抄録集 ((一社)日本リウマチ学会)  67回   909 - 909 2023.03

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Investigation of novel biomarkers by multi-omics analysis of systemic lupus erythematosus

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, KIKUCHI Jun, Grant-in-Aid for Early-Career Scientists , Principal investigator

     View Summary

    Initially, we reported that achieving a lupus low disease activity state within 12 months after starting induction therapy in active systemic lupus erythematosus (SLE) patients was associated with clinical outcomes. We then identified changes in peripheral blood immune cells following initiation of induction therapy in active SLE. In particular, we showed that the type of peripheral blood immune cells that fluctuate differed depending on the drug predominantly used as induction therapy. Furthermore, we found that fluctuations in peripheral blood plasmablasts were associated with treatment prognosis. Focusing on lupus nephritis, the analysis of urinary proteins showed that various pathways were associated with the pathogenesis associated with active and interstitial lesions in renal biopsy tissue findings.

  • Optimization of the treatment of systemic lupus erythematosus by immunological classifications

    2015.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Principal investigator

Awards 【 Display / hide

  • 優秀ポスター賞

    2012.09, 日本臨床免疫学会, IL-6阻害剤とTNF阻害剤はRA患者末梢血中のCD4+CD45RO+CCR6+CD161+細胞に異なった影響を及ぼす

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, INTERNAL MEDICINE (RHEUMATOLOGY)

    2024

  • CASE STUDIES OF INTERNAL MEDICINE

    2023

  • CASE STUDIES OF INTERNAL MEDICINE

    2022

  • CASE STUDIES OF INTERNAL MEDICINE

    2021

  • CASE STUDIES OF INTERNAL MEDICINE

    2020

display all >>

 

Memberships in Academic Societies 【 Display / hide

  • 日本内科学会

     
  • 日本リウマチ学会

     
  • 日本臨床免疫学会